

Ocimum Biosolutions Awarded Two New US Patents in the Gene Expression space

Gaithersburg, Md., US and Hyderabad, India – Wednesday, October 15, 2008 - Ocimum Biosolutions has announced issuance of United States Patent No. 7,428,554 which covers the company's proprietary system and method for determining matching patterns within gene expression data and US Patent No. 7426441, which covers methods for determining renal toxins.

The US Patent No. 7,428,554 covers a method for determining matching patterns within gene expression data stored in a database comprising of biological data. This robust methodology helps in retrieving clinically relevant and biologically significant patterns by making optimal use of information imbibed in the biological data which includes biological samples, related information on diseases, medications, tissues and other sample parameters present in the database.

The US Patent No. 7426441 covers the elucidation of global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention also includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

Ms. Anu Acharya, CEO, Ocimum Biosolutions says, "The granting of these patents reflects our continued focus on innovation and commitment to strengthen our intellectual property portfolio. Such cutting-edge research and techniques contribute immensely to our global reputation as a preferred partner for genomic solutions and services with global biotech, pharmaceutical companies and research organizations."

About Ocimum Biosolutions:

Ocimum Biosolutions (and its subsidiary company Gene Logic) is a leading integrated genomics company providing comprehensive genomic reference databases, life science lab information management solutions, GLP-compliant microarray services and essential research consumables. Over 2/3rd of the top 25 pharma companies, leading research institutes and emerging biotech companies worldwide have chosen Ocimum as their preferred outsourcing partner and utilize Ocimum's expertise for understanding underlying mechanisms of diseases, discovery and prioritization of gene targets and biomarkers.

Gene Logic is a preferred outsourcing partner for providing integrated biorepository and genomic services for several global pharmaceutical companies. Gene Logic's global infrastructure, standardized procedures, capacity, expertise and highly skilled staff support drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. In creating the world's largest commercial gene expression databases – BioExpress® and ToxExpress®, Gene Logic has expertise and capabilities that are unparalleled in the genomic services industry. Gene Logic provides multiple GLP-compliant platforms for gene expression and SNP genotyping data generation, full biorepository and genomic services support for the Genetic Alliance, which is an umbrella organization representing ~600 genetic advocacy groups. Besides providing the physical infrastructure for storing thousands of biological samples, Gene Logic provides services to assist sample accrual, IRB approvals, CRO training, sample collection, clinical data capture and management.

For more information, please visit:
www.ocimumbio.com | www.genelogic.com

Customer & Media Contacts:

Ashwin Sivakumar, PhD
Director – Marketing Alliances and Outreach, Ocimum Biosolutions
Phone: +91-40-66627200
Email: pr@ocimumbio.com

Investor Contact:

Anuradha Acharya
CEO, Ocimum Biosolutions
Email: ceo@ocimumbio.com